Results from the CheckMate -275 trial, in which Opdivo confirmed objective response rate (ORR), the primary endpoint, of 19.6% (95% CI 15.0 – 24.9) in platinum-refractory patients with metastatic urothelial carcinoma, said Bristol-Myers Squibb, the drug’s sponsor.
A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with small cell bladder cancer and small cell/neuroendocrine prostate cancer.
